Skip to main content
Top
Published in: The Journal of Obstetrics and Gynecology of India 5/2020

Open Access 01-10-2020 | Breast Cancer | Review Article

Guidance and Standards for Breast Cancer Care in Europe

Authors: Rudy Leon De Wilde, Rajesh Devassy, Luz Angela Torres-de la Roche, Harald Krentel, Vlad Tica, Cristina Cezar

Published in: The Journal of Obstetrics and Gynecology of India | Issue 5/2020

Login to get access

Abstract

The increasing incidence and mortality rates of breast cancer have led to the necessity of initiating and developing clinical practice guidelines in order to optimize cancer control and provide patients with the best care. These guidelines are either national or issued by reputed relevant European societies—like European Society for Medical Oncology. Many of the recommendations are concordant in-between the guidelines. However, there are still considerable discrepancies to be noted between guidelines from different European countries, which could hinder physicians from implementing their recommendations. The present paper summarizes and compares the recommendations included in the various European guidelines.
Literature
1.
go back to reference Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Supplement 5):8–30.CrossRef Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Supplement 5):8–30.CrossRef
3.
go back to reference Brouwers MC, Kerkvliet K, Spithoff KG. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:1152.CrossRef Brouwers MC, Kerkvliet K, Spithoff KG. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:1152.CrossRef
4.
go back to reference Wöckel A, Festl J, Stüber T, et al. Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032/045OL, December 2017)—part 2 with recommendations for the therapy of primary, recurrent and advanced brea. Geburtsh Frauenh. 2018;78(11):1056–88.CrossRef Wöckel A, Festl J, Stüber T, et al. Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032/045OL, December 2017)—part 2 with recommendations for the therapy of primary, recurrent and advanced brea. Geburtsh Frauenh. 2018;78(11):1056–88.CrossRef
5.
go back to reference Wolters R, Regierer A, Schwentner L, et al. A comparison of international breast cancer guidelines: do the national guidelines differ in treatment recommendations? Eur J Cancer. 2012;48:1–11.CrossRef Wolters R, Regierer A, Schwentner L, et al. A comparison of international breast cancer guidelines: do the national guidelines differ in treatment recommendations? Eur J Cancer. 2012;48:1–11.CrossRef
7.
8.
go back to reference Nordenskjöld A, Fohlin H, Albertsson P, et al. No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. Ann Oncol. 2015;26(2015):1149–54.CrossRef Nordenskjöld A, Fohlin H, Albertsson P, et al. No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. Ann Oncol. 2015;26(2015):1149–54.CrossRef
9.
go back to reference Clavier A, Cornou C, Capmas P, et al. Axillary management in breast cancer: the French practice versus recommendations in the post—2011 era. J Gynecol Obstet Biol Reprod. 2016;45(5):451–8.CrossRef Clavier A, Cornou C, Capmas P, et al. Axillary management in breast cancer: the French practice versus recommendations in the post—2011 era. J Gynecol Obstet Biol Reprod. 2016;45(5):451–8.CrossRef
10.
go back to reference Vincent L, Marqueritte F, Uzan J, et al. Review of national and international guidelines for sentinel lymph node biopsy and complementary axillary dissection in breast cancer. Bull Cancer. 2017;104(4):356–62.CrossRef Vincent L, Marqueritte F, Uzan J, et al. Review of national and international guidelines for sentinel lymph node biopsy and complementary axillary dissection in breast cancer. Bull Cancer. 2017;104(4):356–62.CrossRef
15.
go back to reference Newman L. Decision making in the surgical management of invasive breast cancer—part 2: expanded applications for breast-conserving surgery. Oncology. 2017;31(5):415–20.PubMed Newman L. Decision making in the surgical management of invasive breast cancer—part 2: expanded applications for breast-conserving surgery. Oncology. 2017;31(5):415–20.PubMed
18.
go back to reference Edge J, Nietz S. Sentinel lymph node biopsy and neoadjuvant chemotherapy in the management of early breast cancer: safety considerations and timing. S Afr Med J. 2017;107(6):497–500.CrossRef Edge J, Nietz S. Sentinel lymph node biopsy and neoadjuvant chemotherapy in the management of early breast cancer: safety considerations and timing. S Afr Med J. 2017;107(6):497–500.CrossRef
21.
go back to reference Moran MS, Zhao Y, Ma S, et al. Association of radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncol. 2017;3(8):1060–8.CrossRef Moran MS, Zhao Y, Ma S, et al. Association of radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncol. 2017;3(8):1060–8.CrossRef
22.
go back to reference Corradini S, Bauerfeind I, Belka C, et al. Trends in use and outcome of postoperative radiotherapy following mastectomy: a population-based study. Radiother Oncol. 2017;122(1):2–10.CrossRef Corradini S, Bauerfeind I, Belka C, et al. Trends in use and outcome of postoperative radiotherapy following mastectomy: a population-based study. Radiother Oncol. 2017;122(1):2–10.CrossRef
23.
go back to reference Matikas A, Foukakis T, Bergh J. Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. Acta Oncol. 2017;1–9:2017. Matikas A, Foukakis T, Bergh J. Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. Acta Oncol. 2017;1–9:2017.
24.
go back to reference Viala M, Alexandre M, Thezenas S, et al. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision—making in ER+/Her2-pN0 early breast cancer. Breast Cancer Res Treat. 2017;1–11:2017. Viala M, Alexandre M, Thezenas S, et al. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision—making in ER+/Her2-pN0 early breast cancer. Breast Cancer Res Treat. 2017;1–11:2017.
25.
go back to reference Duffy M, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F. Clinical use of biomarkers in breast cancer: updated guidelines from European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;2017(75):284–98.CrossRef Duffy M, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F. Clinical use of biomarkers in breast cancer: updated guidelines from European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;2017(75):284–98.CrossRef
26.
go back to reference Curigliano G, Burstein H, Winer E, et al. De-escalating and escalating treatment for early-stage breast cancer. In: The St. Gallen international expert consensus conference on the primary therapy of early breast cancer. Ann Oncol 2018, p. 1700–1712. https://doi.org/10.1093/annonc/mdx308. Curigliano G, Burstein H, Winer E, et al. De-escalating and escalating treatment for early-stage breast cancer. In: The St. Gallen international expert consensus conference on the primary therapy of early breast cancer. Ann Oncol 2018, p. 1700–1712. https://​doi.​org/​10.​1093/​annonc/​mdx308.
27.
go back to reference Francis P, Regan M, Fleming G. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46.CrossRef Francis P, Regan M, Fleming G. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46.CrossRef
28.
go back to reference Dowsett M, Forbes J, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.CrossRef Dowsett M, Forbes J, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.CrossRef
29.
go back to reference Metzger-Filho O, Giobbie-Hurder A, Mallon E. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. J Clin Oncol. 2015;33(25):2772–9.CrossRef Metzger-Filho O, Giobbie-Hurder A, Mallon E. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. J Clin Oncol. 2015;33(25):2772–9.CrossRef
30.
go back to reference Burns P, Rohrich R, Chung K. The levels of evidence and their role in evidence—based medicine. Plast Reconstr Surg. 2011;128(1):305–10.CrossRef Burns P, Rohrich R, Chung K. The levels of evidence and their role in evidence—based medicine. Plast Reconstr Surg. 2011;128(1):305–10.CrossRef
32.
go back to reference Bell K, Ristovski-Slijepcevic S. Cancer survivorship: why labels matter. J Clin Oncol. 2013;31:409–11.CrossRef Bell K, Ristovski-Slijepcevic S. Cancer survivorship: why labels matter. J Clin Oncol. 2013;31:409–11.CrossRef
33.
go back to reference Theriault R, Carlson R, Allred C, et al. Breast cancer, national comprehensive cancer network. Breast cancer, version 32013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013;11(7):753–60.CrossRef Theriault R, Carlson R, Allred C, et al. Breast cancer, national comprehensive cancer network. Breast cancer, version 32013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013;11(7):753–60.CrossRef
Metadata
Title
Guidance and Standards for Breast Cancer Care in Europe
Authors
Rudy Leon De Wilde
Rajesh Devassy
Luz Angela Torres-de la Roche
Harald Krentel
Vlad Tica
Cristina Cezar
Publication date
01-10-2020
Publisher
Springer India
Published in
The Journal of Obstetrics and Gynecology of India / Issue 5/2020
Print ISSN: 0971-9202
Electronic ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-020-01316-6

Other articles of this Issue 5/2020

The Journal of Obstetrics and Gynecology of India 5/2020 Go to the issue